April 1, 2008 - "CCTA may be used as a cost-efficient alternative to nuclear stress testing for evaluation of patients with suspected coronary artery disease,"? said James Min, M.D., New York-Presbyterian Hospital and Weill Medical College of Cornell University, NY, at at the American College of Cardiology (ACC) meeting in Chicago, IL. The report concluded 64-slice coronary CT angiography (CCTA) is more cost-effective in patients without a prior coronary artery disease (CAD) diagnosis, while SPECT myocardial perfusion imaging retains a cost advantage in patients with known coronary artery disease. In the study, researchers examined claims from health plans covering more than 10 million individuals, using ICD-9 codes to identify 142,535 patients with suspected CAD who underwent either coronary CTA or SPECT. Data was matched to 2,313 patients undergoing CTA, and 9,252 undergoing SPECT imaging (for both exams mean age 53, 41.5 percent female, 10.6 percent with diabetes mellitus, 40 percent hypertension, 52.5 percent hyperlipidemia, 16.2 percent known CAD), and five other risk factors. Patient costs and outcomes were tracked for Over nine months before and after the exam, researchers tracked patient costs and outcomes, and assessed cardiac risk based on each patient's risk factors and medications. Investigators then calculated the costs of the disease after both tests, and recorded adverse events, including myocardial infarction, angina and hospitalizations related to coronary artery disease. After multivariate adjustment, the downstream costs of coronary artery disease for patients without a prior CAD diagnosis were lower in CTA patients by $603 (95 percent confidence index [CI] $244-$2,053, p < 0.001) compared to the SPECT group. For the 16.2 percent of patients with known CAD, however, costs were lower in the SPECT group by $2,451 (95 percent CI $1,474-$4,068, p < 0.001) compared to CTA. There were no significant differences between CTA and SPECT in myocardial infarction rates (0.7 percent versus 0.8 percent), incident angina (3.8 percent versus 4.0 percent), or CAD-related hospitalizations (0.2 percent vs. 0.2 percent), according to the report. For more information: www.acc08.org
If you enjoy this content, please share it with a colleague
Related Content
Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...
July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...
News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...
July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...
July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...
July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...
July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...
July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...
June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...
May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...